2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 076

COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Abstract Number: 077

Clinical Characteristics of Chronic Recurrent Multifocal Osteomyelitis or Chronic Nonbacterial Osteomyelitis in Pediatrics; Single Center Study in Korea
Abstract Number: 078

Periodic Fever Syndrome and Myelodysplastic Syndrome: Possible Connections Between Two Disorders
Abstract Number: 079

Dynamics of Neutrophil Activation in Repeated TLR-9-Induced Mouse Model of Macrophage Activation Syndrome
Abstract Number: 080

Analysis of Proteasomal Activity – a Potential Diagnostic Tool for Proteasome-associated Autoinflammatory Syndromes (PRAAS)
Abstract Number: 081

Predicting Extension in Juvenile Idiopathic Arthritis
Abstract Number: 082

Globalization and Real-World Implementation of an International Pediatric Rheumatology Learning Resource
Abstract Number: 083

Running out of Rheum: Where Are the Pediatric Rheumatology Faculty?
Abstract Number: 084

Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic
Abstract Number: 085

Identification of Barriers to Care Experienced by Children with Rheumatic Disease: A Qualitative Study
Abstract Number: 086

Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center
Abstract Number: 087

Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Abstract Number: 088

Quality Improvement Cycles to Actualize Distribution of the Adolescent Assessment of Preparation for Transition (ADAPT) Survey
Abstract Number: 089

The Mosaic of Mental Health: Perceived Impact of a Workshop Empowering Pediatric Rheumatology Clinicians in Routine Screening and Effective Management of Mental Health Problems
Abstract Number: 090

Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].